Immunometabolism

Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis Organisation

Retrieved on: 
Monday, January 8, 2024
Human, Treatment, Chronic pain, Homeostasis, PLXDC2, Ulcer, Disease, UC, Doctor of Philosophy, ECCO, Pharmacokinetics, NLRX1, Abstract, UZ Leuven, Library, Congress, European, Effect, Inflammatory Bowel Diseases, Inflammation, Patient, Translation, Immunometabolism, Safety, Landos, NEXUS, Pharmaceutical industry

The abstracts highlight new and additional data on immunometabolism modulation by activating NLRX1 and PLXDC2 with novel agonists such as NX-13 and LABP-69.

Key Points: 
  • The abstracts highlight new and additional data on immunometabolism modulation by activating NLRX1 and PLXDC2 with novel agonists such as NX-13 and LABP-69.
  • The ECCO congress will take place February 21-24, 2024 in Stockholm, Sweden.
  • We are excited to present data from multiple studies including the impact of NX-13 on eosinophil infiltration and visceral hypersensitivity, as well as confirming its relevancy in multiple models and species.
  • Additionally, we are pleased to share new preclinical insights into the potential role of PLXDC2 in ulcerative colitis,“ said Fabio Cataldi, M.D., Executive Vice-President & Chief Medical Officer at Landos.

Sitryx raises additional $39 million to progress development of disease-modifying therapeutics for chronic autoimmune and inflammatory disease

Retrieved on: 
Wednesday, September 27, 2023
University of Oxford, GSK, Therapy, Health, Sofinnova, Research, Immunometabolism, Science, Oxford Sciences Enterprises, Eli Lilly and Company, Lilly, Metabolism, Immune system, Growth, OSE, Inflammation, Pharmaceutical industry, Vaccine

New investor Oxford Science Enterprises (OSE) has joined existing healthcare investors SV Health Investors, Eli Lilly & Company (Lilly), Sofinnova Partners, Longwood Fund and GSK.

Key Points: 
  • New investor Oxford Science Enterprises (OSE) has joined existing healthcare investors SV Health Investors, Eli Lilly & Company (Lilly), Sofinnova Partners, Longwood Fund and GSK.
  • Sitryx will use the proceeds to progress its immunometabolism-targeting therapies into clinical development.
  • Our broad pipeline of potential therapeutics that intervene in cell metabolism offers the potential to rebalance the immune system and achieve disease remission, leading to better patient outcomes.
  • In 2020, Sitryx formed an exclusive global licensing and research collaboration with Lilly, who also became an investor in the Company.

SITRYX THERAPEUTICS ANNOUNCES PARTICIPATION IN UPCOMING CONFERENCES

Retrieved on: 
Thursday, September 8, 2022
The Company, Sofinnova, Degenerative disease, Therapy, GSK, LinkedIn, Lilly, Company, Eli Lilly and Company, Metabolism, Immunometabolism, Pharmaceutical industry, Management, Medicine

Needham Private Biotech Company Virtual 1x1 Forum, Oct. 18-19, 2022

Key Points: 
  • Needham Private Biotech Company Virtual 1x1 Forum, Oct. 18-19, 2022
    Sitryx is a global biopharmaceutical company pioneering the field of immunometabolism.
  • The company's proprietary platform and Product Engine are built on a deep understanding of the intersection of inflammatory signaling and metabolism.
  • In 2018, Sitryx raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK.
  • In 2020, Sitryx formed a global licensing and research collaboration with Eli Lilly and Company.

Sitryx Therapeutics Strengthens Leadership Team With Appointment of Ravi M. Rao as Chief Medical Officer

Retrieved on: 
Tuesday, April 12, 2022
Faculty of Pharmaceutical Medicine, University of Cambridge, Therapy, Company, Faculty, GSK, LinkedIn, Metabolism, Royal college, Degenerative disease, Leadership, Immunometabolism, Sofinnova, Lilly, Group medical practice in the United States, Biotechnology, Head, MB, Cancer, Pharmaceutical medicine, Royal College of Physicians, Roche, GlaxoSmithKline, Oxford BioMedica, Imperial College London, Doctor of Philosophy, Harvard Medical School, Eli Lilly and Company, Lists of diseases, The Company, Development, DBV Technologies, Patient, Disease, Research and development, Pharmaceutical industry, Physician, Research

OXFORD, England, April 12, 2022 /PRNewswire/ --Sitryx Therapeutics Ltd (the "Company"), a biopharmaceutical company pioneering the field of immunometabolism, today announced the appointment of Dr. Ravi M. Rao as its Chief Medical Officer.

Key Points: 
  • OXFORD, England, April 12, 2022 /PRNewswire/ --Sitryx Therapeutics Ltd (the "Company"), a biopharmaceutical company pioneering the field of immunometabolism, today announced the appointment of Dr. Ravi M. Rao as its Chief Medical Officer.
  • "We are delighted to appoint Ravi to this new role of Chief Medical Officer at Sitryx.
  • Dr. Rao joins Sitryx from Swedish Orphan Biovitrum, where he served as Head of Research and Development and Chief Medical Officer leading the development of several medicines in rare diseases across immunology and haematology.
  • Prior to that, he was Chief Medical Officer of Aeglea Biotherapeutics, a company specialising in rare metabolic diseases.

Metabolic Changes in Plasma and Immune Cells Are Associated with COVID-19 Severity and May Predict Patient Survival, Institute for Systems Biology (ISB) Study Shows

Retrieved on: 
Monday, September 6, 2021
Health, Infectious Diseases, Genetics, Clinical Trials, General Health, Biotechnology, Branches of biology, Medical specialties, Clinical medicine, Cancer immunotherapy, COVID-19, T helper cell, Immunotherapy, Immune system, Immunometabolism, La Jolla Institute for Immunology

Researchers from Institute for Systems Biology (ISB), Fred Hutchinson Cancer Research Center and other organizations have uncovered underlying metabolic changes that regulate how immune cells react to COVID-19.

Key Points: 
  • Researchers from Institute for Systems Biology (ISB), Fred Hutchinson Cancer Research Center and other organizations have uncovered underlying metabolic changes that regulate how immune cells react to COVID-19.
  • After examining the blood samples from nearly 200 COVID-19 patients, researchers have uncovered underlying metabolic changes that regulate how immune cells react to the disease.
  • These changes are associated with disease severity and could be used to predict patient survival.
  • The deeper understanding gained here may eventually lead to better therapies that can more precisely target the most problematic immune or metabolic changes.

Rheos Medicines Appoints Industry Leader, John Davis, Jr., M.D., M.P.H., M.S., to Board of Directors

Retrieved on: 
Monday, July 12, 2021
Biotechnology, Pharmaceutical, Health, Life sciences, Biotechnology, Health sciences, Immunology, Immunometabolism, Metabolism, Biopharmaceutical, Rheumatology

Rheos Medicines , a biopharmaceutical company transforming the treatment of autoimmune disease through its metabolic precision medicine (MetPM) platform, today announced the appointment of John Davis, Jr., M.D., M.P.H., M.S.

Key Points: 
  • Rheos Medicines , a biopharmaceutical company transforming the treatment of autoimmune disease through its metabolic precision medicine (MetPM) platform, today announced the appointment of John Davis, Jr., M.D., M.P.H., M.S.
  • We are pleased to welcome John to our board of directors, said Barbara Fox, Ph.D., Chief Executive Officer of Rheos Medicines.
  • from the University of Maryland and completed his training in internal medicine and rheumatology at the University of California, San Francisco.
  • Rheos Medicines is a biopharmaceutical company harnessing insights in immunometabolism to develop novel therapeutics for patients with severe immune-mediated diseases.

Sitryx licenses intellectual property rights for inhibitors of a new target in immunometabolism from Cancer Research UK in exclusive worldwide agreement

Retrieved on: 
Tuesday, July 6, 2021
Medicine, Clinical medicine, Immunology, Immunometabolism, Metabolism, Health, Cancer, Kinase, Targeted therapy

The IP was developed by the Cancer Research UK Beatson Institute within its Drug Discovery Unit.

Key Points: 
  • The IP was developed by the Cancer Research UK Beatson Institute within its Drug Discovery Unit.
  • The new agreement builds on an existing Material Evaluation and Option Agreement between Sitryx and Cancer Research UK for licensed IP relating to small molecule inhibitors of a target kinase, which plays a critical role in a master regulatory metabolic pathway of emerging importance in immune cells and inflammatory processes.
  • Neil Weir, Chief Executive Officer of Sitryx, said: Through our collaborative discussions with Cancer Research UK, we have identified a critical pathway in the area of immunometabolism.
  • Under the terms of the agreement, Cancer Research UK is eligible to receive development, regulatory and commercial milestones and royalty payments on potential sales from immunometabolism targeted therapeutics developed by Sitryx, with such amounts being invested into Cancer Research UKs life-saving research.

Rheos Medicines to Present at Jefferies Virtual Healthcare Conference

Retrieved on: 
Thursday, May 27, 2021
Immunology, Immunometabolism, Metabolism

CAMBRIDGE, Mass., May 27, 2021 /PRNewswire/ -- Rheos Medicines, a biopharmaceutical company transforming the treatment of autoimmune disease through its metabolic precision medicine engine (MetPM) announced that Barbara S. Fox, Ph.D., Chief Executive Officer of Rheos Medicines, will present at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 12:30 p.m. EST.

Key Points: 
  • CAMBRIDGE, Mass., May 27, 2021 /PRNewswire/ -- Rheos Medicines, a biopharmaceutical company transforming the treatment of autoimmune disease through its metabolic precision medicine engine (MetPM) announced that Barbara S. Fox, Ph.D., Chief Executive Officer of Rheos Medicines, will present at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 12:30 p.m. EST.
  • The presentation can be viewed live and will be available online for 30 days following the conference at the following link: https://wsw.com/webcast/jeff174/rhe/1692873
    Rheos Medicines is a biopharmaceutical company harnessing insights in immunometabolism to develop novel therapeutics for patients with severe immune-mediated diseases.
  • Our approach targets the underlying intracellular metabolism of immune cells and has the potential to unlock a new frontier in drug discovery for immune-mediated disease.
  • Rheos was founded by Third Rock Ventures and is located in Cambridge, MA.